Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal recessive congenital ichthyosis in which the cause of the disease is a mutation in the CERS3 gene.
Features include always present findings: Palmar hyperlinearity, Eclabion, Epidermal acanthosis, and Ectropion and others. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 3 | Decreased sweating (hypohidrosis), Congenital nonbullous ichthyosiform erythroderma, Thickened, rough skin (hyperkeratosis) |
CERS3 encodes ceramide synthase 3 (383 aa). Ceramide synthase that catalyzes the transfer of the acyl chain from acyl-CoA to a sphingoid base, with high selectivity toward very- and ultra-long-chain fatty acyl-CoA (chain length greater than C22). Highest expression in Skin Not Sun Exposed Suprapubic (63.1 TPM) and Skin Sun Exposed Lower leg (61.6 TPM).
Autosomal recessive congenital ichthyosis 9 is associated with mutations in the CERS3 gene on chromosome 15.
The CERS3 protein participates in Ceramide synthases transfer acyl-CoA onto sphingoid pathway.
CERS3 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for CERS3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 9 always present features.
No clinical trials have been registered for autosomal recessive congenital ichthyosis 9.
6 publications have been identified in PubMed for autosomal recessive congenital ichthyosis 9. Research spans Basic Science / Preclinical (50%), Case Report / Case Series (33%), and Review / Meta-Analysis (17%).
Hayashi M (2026). [PMID: 42145896](https://pubmed.ncbi.nlm.nih.gov/42145896/). *Case Rep Dermatol*. [Case Report / Case Series]
Dubot P (2025). [PMID: 38706107](https://pubmed.ncbi.nlm.nih.gov/38706107/). *Journal of inherited metabolic disease*. [Basic Science / Preclinical]
Schratter M (2025). [PMID: 40818613](https://pubmed.ncbi.nlm.nih.gov/40818613/). *Journal of lipid research*. [Basic Science / Preclinical]
Xiang R (2025). [PMID: 40709761](https://pubmed.ncbi.nlm.nih.gov/40709761/). *Acta dermato-venereologica*. [Review / Meta-Analysis]
van der Velden JJAJ (2024). [PMID: 39072839](https://pubmed.ncbi.nlm.nih.gov/39072839/). *The Journal of dermatology*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 9:41 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Pregnancy and birth
1 |
Congenital nonbullous ichthyosiform erythroderma |
Mallet S (2024). [PMID: 38581117](https://pubmed.ncbi.nlm.nih.gov/38581117/). *International journal of dermatology*. [Case Report / Case Series]